Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Working Capital Changes: 2020-2025

Historic Other Working Capital Changes for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $4.6 million.

  • Mirum Pharmaceuticals' Other Working Capital Changes rose 20.59% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year increase of 612.43%. This contributed to the annual value of $1.5 million for FY2024, which is 58.39% down from last year.
  • As of Q3 2025, Mirum Pharmaceuticals' Other Working Capital Changes stood at $4.6 million, which was up 13.39% from $4.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $4.6 million during Q3 2025, with a 5-year trough of -$2.1 million in Q2 2022.
  • For the 3-year period, Mirum Pharmaceuticals' Other Working Capital Changes averaged around $1.5 million, with its median value being $1.1 million (2023).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Other Working Capital Changes spiked by 1,281.25% in 2021, and later plummeted by 342.83% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at $1.8 million in 2021, then increased by 14.14% to $2.0 million in 2022, then tumbled by 92.42% to $153,000 in 2023, then plummeted by 98.69% to $2,000 in 2024, then increased by 20.59% to $4.6 million in 2025.
  • Its Other Working Capital Changes was $4.6 million in Q3 2025, compared to $4.1 million in Q2 2025 and $3.0 million in Q1 2025.